---
title: "Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286397318.md"
description: "Citi analyst Samantha Semenkow has reaffirmed a Buy rating for Beam Therapeutics (BEAM) stock, maintaining a $68 price target. The positive outlook is based on the company's strong clinical momentum, including progress towards a pivotal cohort for BEAM-302 and a planned BLA filing for risto-cel by 2026. Recent data supports Beam's efficacy and advantages in treatment outcomes. Bernstein also assigned a Buy rating with a $39 price target, further supporting the positive sentiment around the stock."
datetime: "2026-05-14T10:15:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286397318.md)
  - [en](https://longbridge.com/en/news/286397318.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286397318.md)
---

# Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged

Citi analyst Samantha Semenkow has maintained their bullish stance on BEAM stock, giving a Buy rating yesterday.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Samantha Semenkow has given his Buy rating due to a combination of factors that underscore Beam Therapeutics’ strong clinical and regulatory momentum. The company is moving efficiently toward a pivotal, open-label cohort for BEAM-302 in AATD in the second half of 2026, backed by recent Phase 1/2 data that show a robust efficacy profile with AAT levels in a protective range.

Moreover, Beam is progressing risto-cel toward a planned BLA filing by year-end 2026, supported by data highlighted in a NEJM publication that point to meaningful advantages in efficacy, engraftment speed, hospitalization time, and manufacturing. Additional upcoming milestones, including initial BEAM-301 data in GSD1a and an IND for BEAM-304 in PKU, together with updated financial modeling and an unchanged $68 price target, reinforce her positive risk/reward view and support the Buy recommendation.

In another report released yesterday, Bernstein also assigned a Buy rating to the stock with a $39.00 price target.

### Related Stocks

- [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 | BEAM Stock News](https://longbridge.com/en/news/286289165.md)
- [Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances](https://longbridge.com/en/news/287103341.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)